Literature DB >> 18486551

Prognostic value of cardiopulmonary exercise testing in children with heart failure secondary to idiopathic dilated cardiomyopathy in a non-beta-blocker therapy setting.

Guilherme Veiga Guimarães1, Veridiana Moraes d'Avila, Paulo Roberto Camargo, Luiz Felipe Pinho Moreira, Jose Ramon Lanz, Jose Ramon Lanz Luces, Edimar Alcides Bocchi.   

Abstract

BACKGROUND: Peak oxygen consumption and resting left ventricular ejection fraction (LVEF) are independent predictors of survival in adult heart failure (HF) patients. AIM: To evaluate these factors in children.
METHODS: We prospectively studied 31 children with NYHA class I to III HF (mean LVEF 26+/-10%; mean age 8.6+/-1.9 years). All had dilated cardiomyopathy and were awaiting heart transplantation. A cardiopulmonary treadmill exercise test was performed and LVEF determined by radionuclide ventriculography.
RESULTS: During a median follow-up of 1282 days, 20 children reached at least one end-point (death or heart transplantation). Clinical data from the 11 children without events and the 20 children with events are as follows: NYHA class 1+/-0 vs. 2+/-0.9 (p<0.01); SBP 118+/-17 vs. 102+/-16 (p=0.01); DBP 70+/-10 vs. 61+/-10 (p=0.02); heart rate 165+/-22 vs. 148+/-22 (NS); double-product 19+/-4 vs. 15+/-4 (p=0.01); end-tidal carbon dioxide tension (PetCO2) 35+/-5 vs. 30+/-6 (NS); oxygen consumption (VO2) 22+/-5.4 vs. 18.3+/-5.7 (NS); exercise time 19+/-4 vs. 13+/-6 (p<0.003), and LVEF 31+/-8 vs. 22+/-10 (p=0.02). These variables all correlated with prognosis on univariate analysis. In multivariate analysis, only decreasing exercise time and LVEF were predictive of events during follow-up (p<0.001 and 0.04).
CONCLUSION: These findings suggest that reduction in LVEF and exercise tolerance in children with heart failure is predictive of functional status.

Entities:  

Mesh:

Year:  2008        PMID: 18486551     DOI: 10.1016/j.ejheart.2008.04.009

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  7 in total

Review 1.  The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision.

Authors:  Robert D Ross
Journal:  Pediatr Cardiol       Date:  2012-04-05       Impact factor: 1.655

2.  Pressure-Strain Loops, a Novel Non-invasive Approach for Assessment of Children with Cardiomyopathy.

Authors:  Doaa M Aly; Michael Nguyen; Scott Auerbach; Christopher Rausch; Bruce Landeck; Michael V DiMaria
Journal:  Pediatr Cardiol       Date:  2022-04-11       Impact factor: 1.838

3.  Exercise Capacity and Cardiorespiratory Fitness in Children with Congenital Heart Diseases: A Proposal for an Adapted NYHA Classification.

Authors:  Daniel Neunhaeuserer; Francesca Battista; Barbara Mazzucato; Marco Vecchiato; Giulia Meneguzzo; Giulia Quinto; Josef Niebauer; Andrea Gasperetti; Vladimiro Vida; Giovanni Di Salvo; Maurizio Varnier; Andrea Ermolao
Journal:  Int J Environ Res Public Health       Date:  2022-05-12       Impact factor: 4.614

4.  Importance of treadmill exercise time as an initial prognostic screening tool in patients with systolic left ventricular dysfunction.

Authors:  Eileen Hsich; Eiran Z Gorodeski; Randall C Starling; Eugene H Blackstone; Hemant Ishwaran; Michael S Lauer
Journal:  Circulation       Date:  2009-06-15       Impact factor: 29.690

5.  Functional Class in Children with Idiopathic Dilated Cardiomyopathy. A pilot Study.

Authors:  Aline Cristina Tavares; Edimar Alcides Bocchi; Guilherme Veiga Guimarães
Journal:  Arq Bras Cardiol       Date:  2016-05-06       Impact factor: 2.000

6.  Appropriate scaling approach for evaluating peak VO2 development in Southern Chinese 8 to 16 years old.

Authors:  Clare C W Yu; Ali M McManus; Chun T Au; Hung K So; Adrienne Chan; Rita Y T Sung; Albert M Li
Journal:  PLoS One       Date:  2019-03-12       Impact factor: 3.240

7.  The 20 m shuttle run is not a valid test of cardiorespiratory fitness in boys aged 11-14 years.

Authors:  Jo Welsman; Neil Armstrong
Journal:  BMJ Open Sport Exerc Med       Date:  2019-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.